Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Abstract

A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe-critical disease, including hospitalization and death. Safety appeared to be similar to that in other phase 3 trials of Covid-19 vaccines. (Funded by Janssen Research and Development and others; ENSEMBLE ClinicalTrials.gov number, NCT04505722.).

Keywords

MedicinePlaceboInternal medicineConfidence intervalPopulationVaccine efficacyRandomized controlled trialGastroenterologyImmunologyVaccinationPathology

MeSH Terms

Ad26COVS1AdolescentAdultAgedAsymptomatic DiseasesCOVID-19COVID-19 VaccinesDouble-Blind MethodFemaleHospitalizationHumansImmunogenicityVaccineIncidenceMaleMiddle AgedPatient AcuityProportional Hazards ModelsYoung Adult

Affiliated Institutions

Related Publications

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu Bennet , Jayanthi Wolf , Rodrigo Laureano +1 more

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...

2020 Toxicologic Pathology 47 citations

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack , Stephen J. Thomas , Nicholas Kitchin +26 more

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral...

2020 New England Journal of Medicine 14917 citations

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

Meagan Bolles , Meagan E. Deming , Kristin A. Long +8 more

ABSTRACT Severe acute respiratory syndrome coronavirus (SARS-CoV) is an important emerging virus that is highly pathogenic in aged populations and is maintained with great diver...

2011 Journal of Virology 500 citations

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 23
Pages: 2187-2201
Citations: 2522
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2522

OpenAlex

Influential

2249

CrossRef

Cite This

APA Style

                            
                                
                                    Lawrence Corey, 
                                
                                    Nancy Cauwenberghs, 
                                
                                    Tamzin Tanner
                                
                                et al.
                            
                            (2021). 
                            Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. 
                            New England Journal of Medicine
                            , 384
                            (23)
                            , 2187-2201.
                            https://doi.org/10.1056/nejmoa2101544
                        

Identifiers

DOI: 10.1056/nejmoa2101544
PMID: 33882225
PMCID: PMC8220996

Data Quality

Data completeness: 90%